← Back

Cheng Du Sheng Nuo Biotec Co. Ltd. A

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. It provides semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, degarelix, cetrorelix, plecanatide, and desmopressin acetate. ChengDu ShengNuo Biotec Co.,Ltd. was founded in 2001 and is based in Chengdu, China.

Price · split & dividend adjusted
News & notes moving 688117.CG
688117.CG

Shengnuo Bio's 2026 interim net profit hits 135 million yuan, up 51.98% year on year

Shengnuo Bio released its 2026 interim report, with net profit attributable to the parent company at 135 million yuan, up 51.98% from the same period last year. Total operating revenue was 507 million yuan, up 50.27% year on year, marking four consecutive years of growth. Net cash inflow from operating activities was 87.23 million yuan, up 6.82% year on year. The company's latest asset-liability ratio was 44.80%, gross margin was 58.73%, ROE was 11.82%, and diluted earnings per share was 0.61 yuan.
Jiemian·7dRead more ▾
688117.CG

Shengnuo Bio Releases 2026 Interim Report with Net Profit of 135 Million Yuan

Shengnuo Bio released its 2026 interim report, with net profit attributable to the parent company of 135 million yuan. The company's total operating revenue was 507 million yuan, and net cash inflow from operating activities was 87.2257 million yuan. The latest asset-liability ratio was 44.80 percent, up 0.80 percentage points from the previous quarter and up 1.35 percentage points from the same period last year. The latest gross margin was 58.73 percent, down 1.13 percentage points from the previous quarter. The latest return on equity was 11.82 percent, and diluted earnings per share was 0.61 yuan.
Jiemian·7dRead more ▾
688117.CG

Shengnuo Bio first-half net profit attributable to parent 135 million yuan, up 52% year on year

Shengnuo Bio released its 2026 half-year report. Net profit attributable to the parent in the first half was 135 million yuan, up 52% year on year. Operating revenue was 507 million yuan, up 50.3% year on year. Net profit attributable to the parent after deducting non-recurring items was 134 million yuan, up 50.2% year on year. Net operating cash flow was 87.23 million yuan, up 6.8% year on year. Second-quarter operating revenue was 263 million yuan, up 71.6% year on year, and net profit attributable to the parent was 68.83 million yuan, up 64.5% year on year. As of the end of the second quarter, total assets were 2.072 billion yuan, up 7.1% from the end of the previous year, and net assets attributable to the parent were 1.144 billion yuan, up 8.2% from the end of the previous year. The company continued to advance research, development and production services for peptide innovative drugs, strengthened the conversion and delivery of peptide CDMO projects, and obtained marketing authorization approvals for multiple active pharmaceutical ingredients.
财中社·7dRead more ▾
688117.CG3

Multiple Companies on Shanghai and Shenzhen Exchanges Release Earnings Forecasts and Major Announcements

On the evening of July 12, multiple listed companies on the Shanghai and Shenzhen exchanges released important announcements. StarNeto clarified that its satellite communication business is unrelated to the breakthrough in sea recovery technology for the Long March 10B carrier rocket, and that revenue from new businesses such as the low-altitude economy accounts for less than 5%. Zhezhong Co., Ltd. cautioned that there is uncertainty in converting new orders signed in 2026 into revenue, and that revenue from its main business of complete switchgear has continued to decline. Juli Sling was fined 4.5 million yuan by the Hebei Securities Regulatory Bureau for misleading statements on an interactive platform. The controlling shareholder of Western Region Gold, Xinjiang Nonferrous Metals, plans to merge entirely with Xinjiang Geology and Mining Investment Group, with the actual controller remaining unchanged. In terms of earnings, Yuehai Feed's net profit for the first half of the year is expected to increase by 965.92% to 1302.52%, Ningbo Fubon is expected to increase by 416.54% to 519.85%, Shanshan Co., Ltd. is expected to increase by 262% to 334%, Sanyou Chemical is expected to increase by about 129%, Yalian Machinery's flash report shows net profit growth of 60.06%, Shengnuo Bio is expected to increase by 43.23% to 64.79%, and both Rundu Pharma and China Satellite are expected to turn losses into profits year-on-year. In addition, Taikang Life Insurance plans to reduce its stake in Guoke Hengtai by no more than 3%, and Hengtong Co., Ltd. plans to invest in a digital smart industrial park in Indonesia, with a planned investment of no more than 2 billion yuan.
Eastmoney·46dRead more ▾
688117.CG

Multiple A-share companies sharply raise first-half earnings forecasts

On the evening of July 12, several A-share listed companies disclosed earnings forecasts, sharply raising their first-half performance estimates. Ningbo Fubang expects net profit of 50 million to 60 million yuan, up 416.54% to 519.85% year-on-year, with its core business having shifted to the production and sale of electrical contact materials. Shanshan Co. expects net profit of 750 million to 900 million yuan, up 262% to 334% year-on-year, with its two main businesses, anode materials and polarizer operations, together expected to achieve net profit of 880 million to 950 million yuan. Yuehai Feed expects net profit of 38 million to 50 million yuan, up 965.92% to 1,302.52% year-on-year. In addition, Sanyou Chemical's net profit is expected to rise about 129% year-on-year, Shengnuo Bio's net profit is expected to rise 43.23% to 64.79% year-on-year, and both China Satellite and Rundu Pharma expect to turn losses into profits year-on-year. Yalian Machinery disclosed a performance flash report, with first-half revenue of 515 million yuan, up 36.93% year-on-year, and net profit of 157 million yuan, up 60.06% year-on-year.
证券时报·46dRead more ▾